Unibios Holdings S.A (BIOSK) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Unibios Holdings S.A stock €1.49, price €2.07, that is 27.8% below the price, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range €0.3962 – €3.18 · fair‑value band €1.07 – €1.91 · the €2.07 price screens above the €1.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Unibios Holdings in your weekly email
Every Wednesday you see whether Unibios Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Unibios Holdings S.A., through its subsidiaries, develops and installs water treatment and recycling systems in Europe, Africa, and the Middle East. It provides installation and rental of faced scaffolding; and maintains and installs heating and air conditioning equipment.
Show moreShow less
The company was formerly known as Biossol SA and changed its name to Unibios Holdings S.A. in July 2008. Unibios Holdings S.A. was incorporated in 1940 and is based in Ano Liosia, Greece.
Stock analysis
Unibios Holdings S.A (BIOSK) currently trades at €2.07, while our model-based Fair Value estimate is €1.49, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €1.85 per share, and 1 of the 14 models we run sit above the €2.07 price.
Bear case: the Earnings-Based group reads lowest at €0.7500, and 13 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: €1.07 (bear) to €1.91 (bull), the price of €2.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Industrials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Unibios Holdings S.A reported revenue of €13.9M in FY2025 versus €8.5M in FY2021, a compound +13.1%/yr. Reported net income was €1.7M in FY2025, compounding +49.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap €36.2M Micro · P/E ratio 25.6 · P/S ratio 3.07 · Net margin 0.9% · Return on equity −0.2% · Return on assets (EBIT) 5.5% (5-year average) · Operating margin 3.1% · Revenue (TTM) €15.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 3% fair-value upside, at −28%, BIOSK screens richer than that median.
Fair Value models
Bear€1.07Fair Value €1.49Bull€1.91
Price €2.07 · Downside -27.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +8.0% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +18.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 12%
⚠ Revenue per share shrinking 9.6%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 61% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 86 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Unibios Holdings S.A (BIOSK) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €1.49 versus a price of €2.07, about 28% lower (overvalued).
What is the fair value of BIOSK?
Our model-based fair value for Unibios Holdings S.A is €1.49 (as of Nov 9, 2026), built from audited fundamentals. The current price: €2.07.
What is the quality score of BIOSK?
Unibios Holdings S.A has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Unibios Holdings S.A (BIOSK)?
Our model-based price target is the fair value of €1.49 (as of Nov 9, 2026) from 14 valuation models. Cautious scenario €1.07, optimistic scenario €1.91. It is a calculation from audited fundamentals, not an analyst target.
What is the Unibios Holdings S.A stock forecast for 2026?
Our models put fair value at €1.49, about 28% lower versus a price of €2.07 (overvalued). Cautious scenario €1.07, optimistic scenario €1.91. The calculation is refreshed regularly with new filings.
What is the revenue of Unibios Holdings S.A (BIOSK)?
Unibios Holdings S.A reported trailing-twelve-month revenue of about €15.2M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Unibios Holdings S.A (BIOSK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Unibios Holdings S.A it is €1.49 per share (as of Nov 9, 2026), against a price of €2.07. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Unibios Holdings S.A stock overvalued or undervalued in 2026?
As of Nov 9, 2026, BIOSK trades above its calculated fair value: price €2.07, fair value €1.49, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOSK?
No. The price is what the market pays today (€2.07); the fair value is what the company's own numbers justify (€1.49). For Unibios Holdings S.A the two are €0.5750 per share apart. That gap is exactly why we show both numbers side by side.
How much is Unibios Holdings S.A worth?
The market values Unibios Holdings S.A at about €36.2M (market capitalisation, as of Nov 9, 2026). Per share that is €2.07; our models calculate a fair value of €1.49 per share.
What do the bullish and bearish scenarios say about BIOSK?
Our models span a range for Unibios Holdings S.A: cautious scenario €1.07, base €1.49, optimistic €1.91 per share (as of Nov 9, 2026, price €2.07). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOSK?
Unibios Holdings S.A trades at a price-to-earnings ratio of 25.6 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.49 is built from several models across several years.
How solid is the balance sheet of Unibios Holdings S.A (BIOSK)?
Balance-sheet figures for Unibios Holdings S.A (as of Nov 9, 2026): return on equity −0.2%, debt of 0.22 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is BIOSK from its 52-week high?
Unibios Holdings S.A trades at €2.07, about 34% below its 52-week high of €3.12 and 2% above the low of €2.02 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.49 is for.
Which stocks are comparable to Unibios Holdings S.A?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, Fujian Longking Co, Munters Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Unibios Holdings S.A stock attractive at the current price?
The data as of Nov 9, 2026: price €2.07, calculated fair value €1.49 (−28%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOSK calculated?
We run Unibios Holdings S.A through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.49 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Unibios Holdings S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Unibios Holdings S.A (BIOSK)?
The closing price on Nov 6, 2026 was €2.07. Our model-based fair value is €1.49, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Unibios Holdings S.A right now?
The price sits above even our optimistic bull case (€1.91). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Unibios Holdings S.A
How large is the market capitalisation of Unibios Holdings S.A (BIOSK)?
The market capitalisation of Unibios Holdings S.A is €36.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Unibios Holdings S.A (BIOSK)?
The price-to-sales ratio of Unibios Holdings S.A is 3.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Unibios Holdings S.A (BIOSK)?
The net margin of Unibios Holdings S.A is 0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Unibios Holdings S.A (BIOSK)?
The return on equity (ROE) of Unibios Holdings S.A is −0.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Unibios Holdings S.A (BIOSK)?
On an EBIT basis the return on assets of Unibios Holdings S.A is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Unibios Holdings S.A (BIOSK)?
The operating margin of Unibios Holdings S.A is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Unibios Holdings S.A (BIOSK)?
Revenue at Unibios Holdings S.A is growing +19.9% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Unibios Holdings S.A (BIOSK)?
Earnings per share at Unibios Holdings S.A are growing −78.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Unibios Holdings S.A (BIOSK) generate?
The free cash flow of Unibios Holdings S.A is −€1.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Unibios Holdings S.A (BIOSK) carry?
The net debt of Unibios Holdings S.A is €3.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Unibios Holdings S.A in the live analysis
One click puts Unibios Holdings S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026